Table 1.
Baseline characteristics of all subjects in the discovery cohort.
| Baseline characteristics | All subjects (N = 494)a | Tertile 1 (n = 165)a | Tertile 2 (n = 165)a | Tertile 3 (n = 164)a | p-valueb |
|---|---|---|---|---|---|
| Ages (years) | 43 (36, 54) | 41 (35, 52) | 45 (37, 55) | 45 (35, 55) | 0.18 |
| Male (%) | 71.05 | 71.52 | 72.73 | 68.90 | 0.74 |
| BMI (kg/m2) | 28.0 (25.6, 31.0) | 28.4 (26.6, 31.2) | 27.7 (25.4, 30.4) | 28.0 (25.5, 31.5) | 0.22 |
| Diabetes mellitus (%) | 27.53 | 23.03 | 28.48 | 31.10 | 0.25 |
| Hypertension (%) | 16.80 | 16.36 | 14.55 | 19.51 | 0.48 |
| History of CVD (%) | 9.51 | 9.09 | 11.52 | 7.93 | 0.53 |
| History of LLT (%) | 14.37 | 12.12 | 18.79 | 12.20 | 0.14 |
| LDL cholesterol (mg/dL) | 3.03 (2.49, 3.66) | 3.75 (3.22, 4.12) | 2.97 (2.50, 3.43) | 2.52 (2.11, 2.99) | <0.001 |
| HDL cholesterol (mg/dL) | 1.15 (0.98, 1.33) | 1.15 (1.00, 1.34) | 1.10 (0.95, 1.29) | 1.16 (1.01, 1.33) | 0.11 |
| Total cholesterol (mg/dL) | 4.94 (1.00) | 5.60 (0.87) | 4.78 (0.89) | 4.43 (0.85) | <0.001 |
| Triglycerides (mg/dL) | 1.67 (1.20, 2.49) | 1.67 (1.23, 2.52) | 1.71 (1.29, 2.63) | 1.64 (1.08, 2.23) | 0.169 |
BMI, body mass index; CVD, cardiovascular disease; HDL, high density lipoprotein; LDL, low density lipoprotein; LLT, lipid-lowering therapy.
a
Median (IQR); mean (SD); n (%).
b
Kruskal–Wallis rank sum test; one-way ANOVA; Pearson’s chi-squared test.